• Burkina Faso ends Target Malaria, a GMO mosquito project funded by the Gates Foundation.

• The government cites biosafety risks, low impact, and scientific sovereignty in halting the program.

• The fight against malaria continues with vaccines, drug prevention, and mosquito net distribution nationwide.

Burkina Faso has announced the termination of the Target Malaria project, a high-profile initiative supported by the Bill & Melinda Gates Foundation and Open Philanthropy that aimed to reduce malaria transmission through genetically modified mosquitoes. The Ministry of Higher Education, Research and Innovation confirmed the decision on August 22, describing it as a necessary step to protect both public health and environmental safety.

Target Malaria, which began operations in Burkina Faso in 2012, was part of a broader international effort to use gene-based technology in disease control. Burkina Faso became the first African country to authorize experimental releases of genetically modified mosquitoes in open fields, placing the nation at the heart of global scientific attention. The project’s approach was to release sterile male Anopheles mosquitoes in order to reduce the reproduction rates of female mosquitoes, which are responsible for transmitting the malaria parasite to humans.

For its backers, which included leading international donors and research institutions, the technology promised to revolutionize the fight against malaria in sub-Saharan Africa. Malaria remains a deadly disease that disproportionately affects the region, despite decades of investment in prevention and treatment programs. Proponents of the initiative argued that suppressing mosquito populations at the genetic level could achieve significant reductions in malaria cases, complementing existing strategies such as insecticide-treated nets and seasonal drug campaigns.

However, Target Malaria faced mounting resistance from the moment field trials were announced. Civil society organizations, local activists, and environmental groups voiced concerns about the ecological risks of releasing genetically modified organisms into natural ecosystems. Critics questioned the lack of long-term data on how altering mosquito populations might affect biodiversity, predator species, and the broader food chain. Communities living near the test sites, such as the village of Souroukoudingan in western Burkina Faso, also complained that they had not been sufficiently informed or consulted before the experiments took place.

The government’s decision to halt the project was based on multiple factors. Officials cited unresolved biosafety questions, concerns over transparency and consent, as well as the limited effectiveness shown by the technology in early results. The Ministry also stressed that Burkina Faso must retain sovereignty over its scientific and health priorities, particularly in contexts where foreign donors and foundations play a central role in financing research. By sealing all research facilities associated with Target Malaria and ordering the destruction of genetically modified samples under strict supervision, the authorities sought to signal both caution and a commitment to safeguarding national interests.

Malaria remains an enormous public health challenge for Burkina Faso. According to UNICEF, the country recorded more than 10.2 million cases of malaria in 2023, including over 500,000 severe cases and more than 5,200 deaths. The disease remains the leading cause of hospital visits and deaths among children under five and continues to place a heavy burden on the country’s healthcare system and economy. Against this backdrop, the government has emphasized that ending Target Malaria does not mean a retreat from its efforts to control the disease.

Instead, Burkina Faso is redirecting its focus toward approaches that are widely considered safer and more effective. In February 2024, the country introduced the RTS,S vaccine, the world’s first malaria vaccine, targeting more than 218,000 children aged between five and 23 months in its initial phase. Early results have shown the vaccine can reduce the incidence of severe malaria and hospitalizations. A second vaccine, R21/Matrix-M, which achieved efficacy levels above 75 percent in clinical trials, received approval from the World Health Organization in 2023 and has been integrated into Burkina Faso’s national strategy with significant involvement from local scientists, including Professor Halidou Tinto, a leading malaria researcher.

The government also continues to rely on large-scale preventive measures. Seasonal chemoprevention, introduced in 2014, covers hundreds of thousands of children each year by providing preventive drug treatment during the rainy season when malaria transmission peaks. Nationwide campaigns distribute insecticide-treated mosquito nets, with support from international partners such as the Global Fund and UNICEF. In addition, Burkina Faso’s own research institutions, including the National Center for Malaria Research and the Institute of Health Sciences Research, are pursuing studies into drug resistance, parasite mutations, and new treatment protocols.

The termination of Target Malaria highlights the tension between global scientific innovation and local political realities. For international supporters of genetic technologies, the halt is a setback that may slow efforts to deploy gene-drive mosquitoes across Africa. For Burkina Faso, however, the decision reflects a more cautious approach, privileging public trust, ecological responsibility, and national sovereignty in the face of complex health challenges.

Ultimately, the move underscores that while experimental approaches may promise breakthroughs, African governments are increasingly determined to evaluate risks, benefits, and societal acceptance before adopting them. Burkina Faso’s commitment to alternative strategies, including vaccines and preventive campaigns, suggests the fight against malaria remains a top priority — but one that will be pursued on terms defined in Ouagadougou, not in Seattle or London.

Idriss Linge